menu
    • menu

    Company profile for Anebulo Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Anebulo was founded with the intention of developing disruptive treatments for substance use disorders, such as cannabinoid intoxication and the broader addiction landscape. Our purpose is to harness our innovative, life-saving therapies to improve the lives of millions of patients and empower those who are struggling with addiction to regain control of their lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Anebulo PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1415 Ranch Road 620 South Austin, TX 78734
    Telephone
    Telephone
    512-598-0931
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.anebulo.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AnebuloP

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anebulo Pharma To Start Self Tender Offer
    Anebulo Pharma To Start Self Tender Offer

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251222042934/en/Anebulo-Pharmaceuticals-Announces-Its-Intent-to-Commence-a-Self-Tender-Offer

    BUSINESSWIRE
    22 Dec 2025
    Share Share
    Anebulo Pharma Reveals Q1 Fy2026 Financials And Updates
    Anebulo Pharma Reveals Q1 Fy2026 Financials And Updates

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113842608/en/Anebulo-Pharmaceuticals-Reports-First-Quarter-Fiscal-Year-2026-Financial-Results-and-Recent-Updates

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    Anebulo Pharma Reveals 2025 Financials And Updates
    Anebulo Pharma Reveals 2025 Financials And Updates

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929522113/en/Anebulo-Pharmaceuticals-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Recent-Updates

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    Anebulo Doses First Patients In Ph 1 IV Selonabant Cannabis Trial
    Anebulo Doses First Patients In Ph 1 IV Selonabant Cannabis Trial

    25 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250925857310/en/Anebulo-Pharmaceuticals-Announces-First-Patients-Dosed-in-Phase-1-Single-Ascending-Dose-Study-of-Intravenous-Selonabant-under-Development-for-Acute-Cannabis-Induced-Toxicity

    BUSINESSWIRE
    25 Sep 2025
    Share Share
    Anebulo Pharma Announces Update on Transaction & Strategic
    Anebulo Pharma Announces Update on Transaction & Strategic

    12 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250912026618/en/Anebulo-Pharmaceuticals-Announces-Update-on-Going-Private-Transaction-and-Strategic-Alternatives

    BUSINESSWIRE
    12 Sep 2025
    Share Share
    Anebulo Pharmaceuticals to Terminate Common Stock Registration
    Anebulo Pharmaceuticals to Terminate Common Stock Registration

    23 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250721219989/en/Anebulo-Pharmaceuticals-Approves-Plan-to-Terminate-Registration-of-Its-Common-Stock

    BUSINESSWIRE
    23 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search